


MACROECONOMIC INDICES

Inflation

According to Federal State Statistics Service's data, the Consumer Price Index was estimated at 101.0% in January 2022 as compared to the previous month, In January 2022, Industrial Producer Price Index was 100.1% as compared to the previous month, in the month-earlier period it had amounted to 100.8%.

Figure 1. Consumer Price Index (compared with the previous period)



Living standard


In December 2021, a gross monthly average wage of corporate employees reached RUB 77994 (USD 1057.98). It accounted for 112.3% compared to December of 2020, and 139.9% compared to the previous period. In December 2021, the real gross wage accounted for 103.6% as compared to December of 2020, and 138.8% against the prior period.

According to estimates¹, real disposable cash incomes increased by 3.1% in 2021 as compared to 2020 (Fig. 2).

Retail turnover

In January 2022, the retail turnover was equal to RUR 3213.4 bil. or 103.6% (at comparable prices) as compared to January of the previous year (Fig. 2).

Figure 2. Real wage and retail turnover



* January-December 2021 vs. January-December 2020.

Industrial Production

According to Federal State Statistics Service's data, Industrial Production Index accounted for 108.6% in January 2022 as compared to the same period in the previous year, and 80.0% as compared to December 2021.

According to Federal State Statistics Service's data, Industrial Production Index of drugs and medical products in January 2022 accounted for 106.8% compared to the relevant period of 2021, and 67.5% as compared to December of 2021.

Domestic production

Table 1 provides the top 10 domestic pharmaceutical manufacturers according to their volumes of sales in all segments of the market based on the results for January 2022.

Figure 1. The top ten Russian chemical and pharmaceutical manufacturers by sales volume in January 2022.

Rank	Manufacturer	RUB mil.
1	Otcpharm	4781.1
2	Biocad	4389.0
3	Stada	2424.8
4	Valenta	2243.0
5	R-Pharm	2039.0
6	Binnopharm	2000.3
7	Pharmasyntez	1691.9
8	Pharmstandart	1518.5
9	Grotex	1445.2
10	Promomed	1383.2

Source - Remedium according to IQVIA's data

Table 2 provides pharmacy sales data from 10 regions of the Russian Federation. Sales (in terms of roubles) increased in all regions in December 2021 compared to the previous month. The highest performance was observed in Krasnodar Krai (+21%), the lowest one in Tatarstan (+4%).

Table 2. Pharmacy sales in the regions, 2021

Region	Pharmacy sales, \$ mil. (wholesale prices)			Growth gain, % (roubles)		
	October 2021	November 2021	December 2021	October/September 21	November/October 21	December/November 21
Moscow	196.5	198.6	235.2	-9%	3%	20%
St. Petersburg	90.5	92.6	105.7	-18%	4%	16%
Krasnodar Krai	60.0	51.7	61.4	-3%	-13%	21%
Krasnoyarsk Krai	30.2	31.1	32.5	3%	4%	6%
Tatarstan	35.3	29.9	30.6	9%	-14%	4%
Rostov Region	37.1	33.0	35.0	2%	-10%	7%
Novosibirsk Region	29.8	30.4	33.9	-6%	4%	13%
Voronezh Region	25.8	20.4	21.4	21%	-20%	7%
Perm	11.4	10.5	11.7	6%	-6%	13%
Tyumen	11.0	10.5	10.9	3%	-3%	5%

Advertising

The largest advertisers and pharmaceutical brand names highly publicized in mass media (TV, radio, press, outdoor advertising) are shown in Tables 3 & 4.

Table 3. Top five advertisers in mass media in January 2022

Rank	Company*	Quantity of broadcasts
1	Abbott Laboratories S.A.	11,403
2	Otcpharm	10,644
3	Sanofi	10,502
4	Johnson & Johnson	9,890
5	GSK Consumer Healthcare	9,270

Source - Remedium according to Mediascope's data

Table 4. Top five trade names in mass media in January 2022

Rank	Brand*	Quantity of broadcasts
1	Gaviscon	2,828
2	Longidaza	2,800
3	Strepsils	2,758
4	Theraflu	2,712
5	Otrivin	2,700

Source - Remedium according to Mediascope's data


* Only drugs registered with National Medicine Register were considered.

¹ Due to switching of Federal State Statistics Service to the updated methodology for calculating real disposable cash incomes of the population, the data are published once a quarter.

RUSSIAN PHARMACY FPP DRUG MARKET: 2021 RESULTS

According to the results of the Retail Audit of FPP (Finished Pharmaceutical Products) in Russian Federation™ IQVIA, at year-end 2021 the sales of drugs in physical terms in the country saw a 4% reduced to 4.472 bil. packs as compared to the same period of 2020. In money terms, the market expanded by 7% in terms of roubles and 5% in terms of dollars. The volume of the market amounted to RUB 996.429 bil. (USD 13.549 bil.) at wholesale prices (Fig. 1). The average cost of an OTC pack at retail prices proved to be higher than the previous year figure: USD 3.72 in 2021 vs USD 3.38 in 2020. At year-end 2021, consumer spending for drugs in Russia averaged to USD 113.94, whereas during the same period a year ago it averaged to USD 107.20.

Figure 1. All-Russia pharmacy market in 2020 – 2021



BAYER (+13%)² and SANOFI (+5%) continued to be the leading manufacturers in the Russian retail market according to the results for 2021 (Table 1). The other three drug manufacturers also showed outperformance. STADA (+10%), ABBOTT (+13%) and GLAXOSMITHKLINE (+10%) moved up to ranks three, seven, and ten, respectively. Note that the latter became the only newcomer of the top-10 ranking. The slow-moving TEVA (+5%) also improved its position by one point. In contrast, SANOFI (-3%), SERVIER (+2%), SANDOZ (-5%) and KRKA (+1%) lost one ranking position each. The total share of the top 10 decreased by 0.8 p.p. compared to the previous year and accounted for 33.5%.

Table 1. The top ten drug manufacturers by pharmacy sales

Rank in the top ten		Manufacturer*	Share in total pharmacy sales, %	
2021	2020		2021	2020
1	1	BAYER	4.9	4.6
2	2	OTCPHARM	4.0	4.1
3	4	STADA	3.7	3.6
4	3	SANOFI	3.6	4.0
5	6	TEVA	3.1	3.2
6	5	SERVIER	3.1	3.2
7	9	ABBOTT	3.0	2.8
8	7	SANDOZ	2.8	3.1
9	8	KRKA	2.8	2.9
10	11	GLAXOSMITHKLINE	2.7	2.7
Total			33.5	34.3

*AIPM members are in bold

Brand XARELTO (+34%) YEAR'S RESULTS continued to show the highest sales volumes in the Russian market at the year-end (Table 2). ARBIDOL (+32%), antithrombotic agent ELIQUIS (+85%) and phlebotropic drug DETRALEX (+14%) moved up to ranks two through four, respectively. The newcomers that broke in the top ten ranking HEPTRAL (+42%) and CARDIOMAGNYL (+12%) showed high growth rates and rose in the ranks, moving up to rank seven and the last line. In contrast, the brands INGAVIRIN (-34%), CONCOR (+1%) and MEXIDOL (+9%) moved down to the lower ranks six, eight and nine. NUROFEN (+10%) held its previous rank five. The total share of the top 10 increased from 7.7% to 8.5%.

Table 2. The top ten brands by pharmacy sales

Rank in the top ten		Brand	Share in total pharmacy sales, %	
2021	2020		2021	2020
1	1	XARELTO	1.5	1.2
2	3	ARBIDOL	1.3	1.0
3	4	ELIQUIS	1.2	0.7
4	6	DETRALEX	0.7	0.7
5	5	NUROFEN	0.7	0.7
6	2	INGAVIRIN	0.7	1.1
7	13	HEPTRAL	0.7	0.5
8	7	CONCOR	0.6	0.6
9	8	MEXIDOL	0.6	0.6

²Hereinafter, unless otherwise stated, growth gains are stated in the rouble equivalent or national currency.

Rank in the top ten		Brand	Share in total pharmacy sales, %	
2021	2020		2021	2020
10	11	CARDIOMAGNYL	0.6	0.5
Total			8.5	7.7

The top ten INN and grouping names ranking appeared to be more stable – four of its INNs held their own in the ranking (Table 3). UMIFENOVIR (+33%), DIOSMIN*HESPERIDIN (+15%), IBUPROFEN (+12%) and PANCREATIN (+3%) held their previous ranks two, five, six and eight, respectively. RIVAROXABAN (+34%) became the leader of the ranking, moving up to rank one from three. NIMESULIDE (+10%) moved up two ranks, coming in at number seven. The newcomers APIXABAN (+85%) and ROSUVASTATIN (+17%) broke into the ranks of the top ten ranking, coming in at numbers four and ten. Two INNs with outperforming but relatively low growth rates, XYLOMETAZOLINE (+8%) and BISOPROLOL (+2%), lost two ranking points each. The total share of the top-ten INNs and grouping names increased from 10.2% to 11.4%.

Table 3. The top 10 INNs and grouping names by pharmacy sales

Rank in the top ten		INNs/Grouping Names	Share in total public segment, %	
2021	2020		2021	2020
1	3	RIVAROXABAN	1.5	1.2
2	2	UMIFENOVIR	1.5	1.2
3	1	XYLOMETAZOLINE	1.4	1.4
4	13	APIXABAN	1.2	0.7
5	5	DIOSMIN*HESPERIDIN	1.1	1.0
6	6	IBUPROFEN	1.1	1.0
7	9	NIMESULIDE	1.0	0.9
8	8	PANCREATIN	1.0	0.9
9	7	BISOPROLOL	1.0	1.0
10	11	ROSUVESTATIN	0.8	0.7
Total			11.4	10.2

C09 Agents acting on the renin-angiotensin system (-0.05%) held the leading positions in the top ten ATC groups ranking (Table 4). N02 Analgesics (+4%), R05 Cough and cold preparations (+11%) and N06 Psychoanaleptics (+12%) rounding out the top ten ranking also remained in their previous positions. The groups M01 Anti-inflammatory and antirheumatic drugs (+10%), B01 Anticoagulants (+25%), G03 Sex hormones (+9%) and R01 Nasal preparations (+10%) showed growth in sales, moving up to ranks two, three, five and six, respectively. At the same time, J05 Antivirals for systemic use (-8%) and J01 Antibacterials for systemic use (-15%), which reduced their sales, moved down to ranks four and seven. In total, the top ten ATC groups accounted for 38.1%, whereas it amounted to 39% in the year-earlier period.

Table 4. The top ten ATC Groups by pharmacy sales


Rank in the top ten		ATC code	ATC group	Share in total pharmacy sales, %	
2021	2020			2021	2020
1	1	C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	5.0	5.4
2	3	M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	4.9	4.8
3	5	B01	ANTITHROMBOTIC AGENTS	4.8	4.1
4	2	J05	ANTIVIRALS FOR SYSTEMIC USE	4.3	5.0
5	6	G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	3.4	3.4
6	7	R01	NASAL PREPARATIONS	3.4	3.3
7	4	J01	ANTIBACTERIALS FOR SYST USE	3.4	4.2
8	8	N02	ANALGESICS	3.1	3.2
9	9	R05	COUGH AND COLD PREPARATIONS	2.9	2.8
10	10	N06	PSYCHOANALEPTICS	2.8	2.7
Total				38.1	39.0

Conclusion. Based on the results for 2021, the retail pharmacy market of the country brought in RUB 1224.8 bil. (USD 16.655 bil.). The growth was positive in terms of roubles (+8%) and in terms of dollars (+6%) as compared to 2020. In pack terms, the market reduced by 4% compared to the prior year and amounted to 4.472 bil. packs. In 2021, the average cost of an FPP pack in the national pharmacies was USD 3.72, whereas in the year-earlier period it was USD 3.38. The average expenses of the Russian Federation residents for purchase of drugs in pharmacies in 2021 grew as compared to the previous year (USD 113.94 vs. USD 107.20).

RUSSIAN FEDERATION HOSPITAL MARKET: 2021 RESULTS

According to the results of the Budget Audit of Finished Pharma Products (FPP) in the Russian Federation (without DLO and regional subsidized drug list)™ IQVIA, at the end of 2021 the country public procurement segment continued to reduce in physical terms (-13%) and amounted to 542.017 mil. packs. In money terms, the market showed a 38% increase in terms of roubles and in terms of dollars and reached RUB 488.912 bil. (USD 6.658 mil.) at wholesale prices. Based on the results for 2021, the average cost of an FPP pack in the hospital sector of the Russian Federation was USD 12.28, whereas in the year-earlier period its cost was USD 7.73.

Figure 1. Moscow public sector in 2020 – 2021



In 2021, all the top ten manufacturers in the public segment showed positive growth rates, most of them – outperformance rates (Table one). 1). The purchases from JOHNSON & JOHNSON (2.1-fold growth in purchases) and R-PHARM (2.5-fold growth) more than doubled, which due to this moved up to ranks four and seven, respectively. Note that the latter became one of two newcomers of the top 10 ranking. The second newcomer BAYER (+60%) rounded out the top ten ranking. The other three manufacturers also rose in the ranks. The Russia-based BIOCAD (+61%) and PHARMASYNTEZ (+81%), as well as NOVARTIS (+88%) moved up to ranks one, five and nine. At the same time, ROCHE (+45%), BRISTOL MYERS (+36%) and PFIZER (+46%) moved down to the lower ranks two, six and eight, respectively. MSD (+29%) continued to hold its previous rank three. In total, based on the results for 2021 the top ten manufacturers accounted for 48.7% of the public segment against 41.7% in the year-earlier period.

Table 1. The top 10 manufacturers by public segment volume

Rank in the top ten		Manufacturer*	Share in total public segment, %	
2021	2020		2021	2020
1	2	BIOCAD RF	7.2	6.2
2	1	ROCHE	7.2	6.9
3	3	MSD	5.8	6.2
4	7	JOHNSON & JOHNSON	5.3	3.5
5	8	PHARMASYNTEZ	4.5	3.4
6	4	BRISTOL MYERS SQU	4.3	4.4
7	12	R-PHARM ZAO RF	4.2	2.4
8	5	PFIZER	4.2	4.0
9	10	NOVARTIS	3.3	2.4
10	11	BAYER	2.7	2.4
Total			48.7	41.7

*AIPM members are in bold

Not a single brand of the top 10 brands ranking managed to hold their ranking (Table 2). At the same time, six of them managed to improve their ranking. KEYTRUDA (+52%) headed the top ten ranking, and the newcomers SPINRAZA (3.9-fold growth in purchases), ILSIRA (17-fold growth), ARTLEGIA (3.2-fold growth), AREPLIVIR (4.4-fold growth) and REMDEFORM moved up to ranks three through five, seven and eight. The less dynamic OPDIVO (+35%), AVEGRA (+2%), PERJETA (+17%) and TIVICAY (+29%), on the contrary, moved down to the lower ranks two, six and the last two, respectively. The total share of the top 10 brands in the public segment expanded from 16.1% to 24.4%.

Table 2. The top 10 brands by public segment volume

Rank in the top ten		Brand	Share in total public segment, %	
2021	2020		2021	2020
1	2	KEYTRUDA	3.7	3.4
2	1	OPDIVO	3.6	3.7
3	15	SPINRAZA	3.1	1.1
4	42	ILSIRA	3.0	0.2
5	13	ARTLEGIA	2.7	1.2
6	4	AVEGRA BIOCAD	1.8	2.4
7	28	AREPLIVIR	1.7	0.5
8	N/A	REMDEFORM	1.6	N/A
9	5	PERJETA	1.6	1.9
10	8	TIVICAY	1.6	1.7
Total			24.4	16.1

The top INN and grouping names ranking leader also changed: FAVIPRAVIR moved up to rank one from seven (3.5-growth in purchases) (Table 3). PEMBROLIZUMAB (+52%) moved up to rank two from three, shifting NIVOLUMAB (+35%) one rank down. The newcomers NUSINERSEN (3.9-fold growth) and LEVILIMAB (17-fold growth) moved up to ranks four and five. Another two newcomers OLOKIZUMAB (3.2-fold growth) and REMDESIVIR (65-fold growth) moved up to ranks seven and nine, respectively. INN VACCINE, INFLUENZA (-12%), which showed negative growth rates, as well as two INNs BEVACIZUMAB (+4%) and PERTUZUMAB (+17%) with positive, but relatively low growth rates moved down to ranks six, eight and the last, respectively. The total share accumulated by the top-ten INNs and grouping names increased from 20.5% to 28.8%.

Table 3. The top ten INNs and grouping names by public segment volume

Rank		INNs/Grouping Names	Share in total public segment, %	
2021	2020		2021	2020
1	7	FAVIPRAVIR	4.5	1.8
2	3	PEMBROLIZUMAB	3.7	3.4
3	2	NIVOLUMAB	3.6	3.7
4	17	NUSINERSEN	3.1	1.1
5	43	LEVILIMAB	3.0	0.2
6	1	VACCINE, INFLUENZA	3.0	4.7
7	14	OLOKIZUMAB	2.7	1.2
8	4	BEVACIZUMAB	1.9	2.5
9	46	REMDESIVIR	1.7	0.0
10	6	PERTUZUMAB	1.6	1.9
Total			28.8	20.5

L01 Antineoplastic agents (+17%) and J05 Antivirals for systemic use (+69%) held the top two ranks in the top ten ATC groups ranking (Table 4). J06 Immune sera and immunoglobulins (+61%) also continued to hold the previous rank ten. The other INNs of the top 10 ranking shifted their ranks; moreover, only three of them improved them. Thus, L04 Immunosuppressants moved up to rank three from six (2.9-fold growth in purchases), B01 Anticoagulants moved up to rank four from five (2.1-fold growth), and the newcomer M09 Other drugs for disorders of the musculo-skeletal system (7.9-fold growth) broke into the ranks of the top ten ranking, coming up to rank six. On the contrary, four groups of the top ten lost ranking positions. It happened in J07 Vaccines (-6%), which showed a negative trend, J01 Antibacterials for systemic use (-0.3%) and B05 Plasma-substituting and perfusion solutions (+0.4%), which demonstrated almost zero growth rates, as well as in group L02 Endocrine therapy (+14%) due to lagging behind average market rates. The total share of the top 10 ATC groups increased by 3.5 p.p. and reached 84.5%.

Table 4. The top 10 ATC groups by public segment volume

Rank		ATC code	ATC group	Share in total public segment, %	
2021	2020			2021	2020
1	1	L01	ANTINEOPLASTIC AGENTS	27.2	32.2
2	2	J05	ANTIVIRALS FOR SYSTEMIC USE	14.9	12.2
3	6	L04	IMMUNOSUPPRESSANTS	9.4	4.5
4	5	B01	ANTITHROMBOTIC AGENTS	7.3	4.8
5	3	J07	VACCINES	7.2	10.6
6	13	M09	OTHER DRUGS FOR DISORD. OF THE MUSCULO-SKELET.SYST	6.5	1.1
7	4	J01	ANTIBACTERIALS FOR SYST USE	5.8	8.1
8	7	B05	PLASMA SUBSTITUTES AND PERFUSION SOLUTIONS	2.7	3.7
9	8	L02	ENDOCRINE THERAPY	2.0	2.4
10	10	J06	IMMUNE SERA & IMMUNO-GLOBULIN	1.5	1.3
Total				84.5	81.0

Conclusion. At the end of 2021, the public segment of Russia expanded by 38% in both rouble and dollar terms, and its volume reached RUB 488.912 bil. (USD 6.657 bil.). In pack terms, the market reduced by 13% and amounted to 542.017 mil. packs. At year-end, the average cost of a finished pharma product (FPP) pack in the public sector of the country amounted to USD 12.28 vs. USD 7.73 in the year earlier period.

PHARMACEUTICAL MARKET OF THE CENTRAL FEDERAL DISTRICT (CFD) IN 2021 KEY PERFORMANCE INDICATORS


Macroeconomic indices

Table 1: Recent statistical data on socio-economic situation in CFD

Value	December-January 2021	December-January 2021 (%) vs. December-January 2020
Industrial production index		122.8
Retail turnover, RUB bil.	13,950.5	109.1
Monthly average accrued wage per worker (nominal), RUB	72,528	110.7
Real wage		103.8

Note: CFD TOGS data

Figure 1. Movement of price index and non-food product price index vs December 2020



Indicators of movement of prices and retail margins (according to IQVIA data)

Figure 1. Movement of weighted average prices and retail margins in 2020-2021





Figure 2. Movement of weighted average purchase prices in 2020– 2021



Indicators of the market movement and profile³ (according to IQVIA data)

Figure 3. CFD pharmaceutical market in 2020– 2021




Figure 4. Major segment pattern of the CFD pharmaceutical market in 2020–2021




Figure 5. Retail segment pattern of CFD pharmaceutical market in 2020– 2021





Figure 6. Movement of the Russian/foreign drugs share in the CFD pharmaceutical market pattern in 2020– 2021



³ Exclusive of Moscow

PHARMACEUTICAL MARKET OF THE NORTH-WESTERN FEDERAL DISTRICT (NWFD) IN 2021 KEY PERFORMANCE INDICATORS


Macroeconomic indices

Table 1: Recent statistical data on socio-economic situation in NWFD

Value	December-January 2021	December-January 2021 (%) vs. December-January 2020
Industrial production index		104.6
Retail turnover, RUB bil.	4,010.4	109.9
Monthly average accrued wage per worker (nominal), RUB	62,921	109.8
Real wage		103.0

Note: NWFD TOGS data

Figure 1. Movement of price index and non-food product price index vs December 2020



Indicators of movement of prices and retail margins (according to IQVIA data)

Figure 1. Movement of weighted average prices and retail margins in 2020-2021





Figure 2. Movement of weighted average purchase prices in 2020–2021



Indicators of the market movement and profile⁴ (according to IQVIA data)

Figure 3. NWFD pharmaceutical market in 2020–2021




Figure 4. Major segment pattern of the NWFD pharmaceutical market in 2020–2021




Figure 5. Retail segment pattern of the NWFD pharmaceutical market in 2020–2021





Figure 6. Movement of the Russian/foreign drugs share in the NWFD pharmaceutical market pattern in 2020–2021



⁴ Exclusive of St. Petersburg

PHARMACEUTICAL MARKET OF THE VOLGA FEDERAL DISTRICT (VFD) IN 2021 KEY PERFORMANCE INDICATORS


Macroeconomic indices

Table 1: Recent statistical data on socio - economic situation in VFD

Value	December-January 2021	December-January 2021 (%) vs. December-January 2020
Industrial production index		106.9
Retail turnover, RUB bil.	6,591.5	105.4
Monthly average accrued wage per worker (nominal), RUB	40,661	109.8
Real wage		102.7

Note: VFD TOGS data

Figure 1. Movement of price index and non-food product price index vs December 2020



Indicators of movement of prices and retail margins (according to IQVIA data)

Figure 1. Movement of weighted average prices and retail margins in 2020-2021





Figure 2. Movement of weighted average purchase prices in 2020– 2021



Indicators of the market movement and profile (according to IQVIA data)

Figure 3. VFD pharmaceutical market in 2020– 2021




Figure 4. Major segment pattern of VFD pharmaceutical market in 2020– 2021




Figure 5. Retail segment pattern of VFD pharmaceutical market in 2020– 2021





Figure 6. Movement of the Russian/foreign drugs share in the VFD pharmaceutical market pattern in 2020– 2021



PHARMACEUTICAL MARKET OF THE URAL FEDERAL DISTRICT (UFD) IN 2021 KEY PERFORMANCE INDICATORS


Macroeconomic indices

Table 1: Recent statistical data on socio-economic situation in UFD

Value	December-January 2021	December-January 2021 (%) vs. December-January 2020
Industrial production index		106.8
Retail turnover, RUB bil.	3,148.6	104.3
Monthly average accrued wage per worker (nominal), RUB	59,624	107.7
Real wage		101.8

Note: VFD TOGS data

Figure 1. Movement of price index and non-food product price index vs December 2020



Indicators of movement of prices and retail margins (according to IQVIA data)

Figure 1. Movement of weighted average prices and retail margins in 2020-2021





Figure 2. Movement of weighted average purchase prices in 2020–2021



Indicators of the market movement and profile (according to IQVIA data)

Figure 3. UFD pharmaceutical market in 2020–2021




Figure 4. Major segment pattern of the UFD pharmaceutical market in 2020–2021




Figure 5. Retail segment pattern of the UFD market in 2020–2020





Figure 6. Movement of the Russian/foreign drugs share in the UFD pharmaceutical market pattern in 2020–2021



PHARMACEUTICAL MARKET OF THE SIBERIAN FEDERAL DISTRICT (SiFD) IN 2020 KEY PERFORMANCE INDICATORS


Macroeconomic indices

Table 1: Recent statistical data on socio-economic situation in SiFD

Value	December-January 2021	December-January 2021 (%) vs. December-January 2020
Industrial production index		102.9
Retail turnover, RUB bil.	3,356.1	105.4
Monthly average accrued wage per worker (nominal), RUB	48,570	109.8
Real wage		102.7

Note: SiFD TOGS data

Figure 1. Movement of price index and non-food product price index vs December 2020



Indicators of movement of prices and retail margins (according to IQVIA data)

Figure 1. Movement of weighted average prices and retail margins in 2020-2021





Figure 2. Movement of weighted average purchase prices in 2020–2021



Indicators of the market movement and profile (according to IQVIA data)

Figure 3. SiFD pharmaceutical market in 2020–2021




Figure 4. Major segment pattern of SiFD pharmaceutical market in 2020–2021




Figure 5. Retail segment pattern of SiFD pharmaceutical market in 2020–2021





Figure 6. Movement of the Russian/foreign drugs share in the SiFD pharmaceutical market pattern in 2020–2021



PHARMACEUTICAL MARKET OF THE SOUTHERN FEDERAL DISTRICT (SoFD) IN 2021 KEY PERFORMANCE INDICATORS


Macroeconomic indices

Table 1: Recent statistical data on socio-economic situation in SoFD

Value	December-January 2021	December-January 2021 (%) vs. December-January 2020
Industrial production index		104.4
Retail turnover, RUB bil.	4,211.2	110.7
Monthly average accrued wage per worker (nominal), RUB	39,460	108.8
Real wage		101.5

Note: SoFD TOGS data

Figure 1. Movement of price index and non-food product price index vs December 2019



Indicators of movement of prices and retail margins (according to IQVIA data)

Figure 1. Movement of weighted average prices and retail margins in 2020-2021





Figure 2. Movement of weighted average purchase prices in 2020–2021



Indicators of the market movement and profile (according to IQVIA data)

Figure 3. SoFD pharmaceutical market in 2020–2021




Figure 4. Major segment pattern of SoFD pharmaceutical market in 2020–2021




Figure 5. Retail segment pattern of SoFD pharmaceutical market in 2020–2021





Figure 6. Movement of the Russian/foreign drugs share in the SoFD pharmaceutical market pattern in 2020–2021



PHARMACEUTICAL MARKET OF THE FAR EASTERN FEDERAL DISTRICT (FEFD) IN 2021 KEY PERFORMANCE INDICATORS


Macroeconomic indices

Table 1: Recent statistical data on socio - economic situation in FEFD

Value	December-January 2021	December-January 2021 (%) vs. December-January 2020
Industrial production index		102.8
Retail turnover, RUB bil.	2,129.4	104.5
Monthly average accrued wage per worker (nominal), RUB	65,640	108.6
Real wage		102.5

Note: FEFD TOGS data

Figure 1. Movement of price index and non-food product price index vs December 2020



Indicators of movement of prices and retail margins (according to IQVIA data)

Figure 1. Movement of weighted average prices and retail margins in 2020-2021





Figure 2. Movement of weighted average purchase prices in 2020– 2021



Indicators of the market movement and profile (according to IQVIA data)

Figure 3. FEFD pharmaceutical market in 2020– 2021




Figure 4. Major segment pattern of FEFD pharmaceutical market in 2020– 2021




Figure 5. Retail segment pattern of FEFD pharmaceutical market in 2020– 2021




Figure 6. Movement of the Russian/foreign drugs share in the FEFD pharmaceutical market pattern in 2020– 2021

